title: Future/novel uses of beta blockers in clinical therapeutics.
abstract: Beta-blocker usage in the United Kingdom centers around propranolol and oxprenolol as noncardioselective drugs, atenolol and metoprolol as cardioselective agents, and pindolol or oxprenolol when partial agonist activity is desired. Any meaningful comparison of a novel beta blocker against the established drugs must be a variable-dose trial, for the optimum dose of any beta blocker that can be tolerated varies widely. Effective beta blockade is considered to have been achieved when the standing heart rate has been lowered to about 55 beats/minute.
authors.forename: D
authors.initials: D
authors.lastname: Maclean
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006321:Heart / Q000187:drug effects; D006801:Humans; D009928:Organ Specificity
chemical_list: D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers